Skip to content

Comparing Dose Of Iron Syrup For Treatment of Iron Deficiency Anemia in Children

Daily Oral Ferrous Sulphate Supplementation at 6mg/Kg Vs 3mg/Kg for Treatment Of Moderate And Severe Iron Deficiency Anemia In Children - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093920
Enrollment
122
Registered
2025-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Ferrous Sulphate at 6mg/kg: Ferrous sulphate syrup at 6mg/kg/day as a single dose for 12 weeks. Control Intervention1: Ferrous sulphate at 3mg/kg: Ferrous sulphate syrup at 3mg/kg/day a

Sponsors

Intramural Research Grant, University College of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children with moderate and severe anemia AND underlying iron deficiency will be included. Moderate anemia defined as Hb- 7-9.4g per dl in children aged 3 months-23 months and Hb-7-9.9 g per dl in children aged 24 months-59 months. Severe anemia will be defined as Hb-less than 7g per dl for all children. Iron deficiency defined with peripheral blood smear suggestive of microcytic hypochromic picture AND low mean corpuscular volume (MCV) (upto 2 year less than 70 fl and 2 to 5 year less than 70 plus age in years AND serum ferritin less than 12 mcg per L in the absence of infection and less than 30 mcg per L in the presence of infection

Exclusion criteria

Exclusion criteria: 1. Children with other causes of anemia - vitamin-B12 deficiency, folic acid deficiency, dimorphic or megaloblastic anemia 2. Apparent non-nutritional etiology of anemia (obvious bleeding, chronic hemolytic anemia, malignancies) 3.Those who have received iron during last 2 weeks 4.Children who received blood/packed cell transfusion within last 3 months 5.Children with known or suspected chronic illness (chronic kidney disease, chronic liver disease, congenital heart disease, chronic infection)

Design outcomes

Primary

MeasureTime frame
Proportion of non-anemic children at 12 weeks of therapyTimepoint: 12 weeks

Secondary

MeasureTime frame
Change in Hemoglobin after therapyTimepoint: 2, 8, 12 weeks;Serum ferritin levelTimepoint: 12 weeks;Proportion of participants compliant to oral therapyTimepoint: 1,2,4,8,12 weeks;Adverse effects experiencedTimepoint: 1,2,4,8,12 weeks;Proportion of non anemic childrenTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Anshu Chandra

Department of Pediatrics, UCMS and GTB Hospital

anshuchandra14@gmail.com9599340269

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026